| 國立成功大學 |
2023 |
Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease inTaiwan: A Prospective Nationwide Registry (VIOLET) Study
|
Lin, W.-C.;Tai, W.-C.;Chang, Chang C.-H.;Tu, C.-H.;Feng, I.-C.;Shieh, M.-J.;Chung, Chung C.-S.;Yen, H.-H.;Chou, J.-W.;Wong, J.-M.;Liu, Y.-H.;Huang, T.-Y.;Chuang, Chuang C.-H.;Tsai, Tsai T.-J.;Chiang, F.-F.;Lu, C.-Y.;Hsu, W.-H.;Yu, F.-J.;Chao, T.-H.;Wu, D.-C.;Ho, A.-S.;Lin, H.-H.;Feng, C.-L.;Wu, K.-L.;Wong, M.-W.;Tung, C.-C.;Lin, C.-C.;Chen, Chen C.-C.;Hu, Hu H.-M.;Lu, Lu L.-S.;Wang, H.-S.;Wu, I.-C.;Kuo, H.-Y.;Wu, J.-F.;Shih, H.Y.;Ni, Y.-H.;Tang, S.-L.;Chen, P.-H.;Wei, S.-C. |
| 國家衛生研究院 |
2023-05 |
Real-world evidence of hyperbaric oxygen therapy on cardiovascular outcomes in patients with chronic osteomyelitis
|
Tai, CJ;Lu, CK;Lee, CY;Lee, SS;Yang, YH |
| 國立成功大學 |
2021 |
Real-world evidence of population differences in allopurinol-related severe cutaneous adverse reactions in East Asians: A population-based cohort study
|
Sato, T.;Cheng, Cheng C.-L.;Park, H.-W.;Kao, Yang Y.-H.;Yang, M.-S.;Fujita, M.;Kumagai, Y.;Tohkin, M.;Saito, Y.;Sai, K. |
| 臺大學術典藏 |
2021-01-28T01:06:14Z |
Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan
|
Kun-Huei Yeh;Yang T.-S.;Hsu T.-C.;Tzu-Liang Chen W.;Chen H.-H.;Teng H.-W.;Lin B.-W.;Kuan F.-C.;Chiang F.-F.;Duann C.-W.;Li Y.-S.;Lin M.-T.;Fiala-Buskies S.;Ducreux M.;Wang J.-Y.; KUN-HUEI YEH; Yang T.-S.; Hsu T.-C.; Tzu-Liang Chen W.; Chen H.-H.; Teng H.-W.; Lin B.-W.; Kuan F.-C.; Chiang F.-F.; Duann C.-W.; Li Y.-S.; Lin M.-T.; Fiala-Buskies S.; Ducreux M.; Wang J.-Y. |
| 臺大學術典藏 |
2021-01-18T09:12:10Z |
Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan
|
KUN-HUEI YEH; Yang, Tsai Sheng; Hsu, Tzu Chi; Tzu-Liang Chen, William; Chen, Hong Hwa; Teng, Hao Wei; Lin, Bo Wen; Kuan, Feng Che; Chiang, Feng Fan; Duann, Chi Wei; Li, Ying Shiuan; Lin, Meng Ting; Fiala-Buskies, Sabine; Ducreux, Michel; Wang, Jaw Yuan |
| 國立成功大學 |
2021 |
Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan
|
Yeh, K.-H.;Yang, T.-S.;Hsu, T.-C.;Tzu-Liang, Chen W.;Chen, H.-H.;Teng, H.-W.;Lin, B.-W.;Kuan, F.-C.;Chiang, F.-F.;Duann, C.-W.;Li, Y.-S.;Lin, M.-T.;Fiala-Buskies, S.;Ducreux, M.;Wang, J.-Y. |
| 臺大學術典藏 |
2020-11-11T08:29:15Z |
Real-world evidence on the safety and effectiveness of fingolimod in patients with multiple sclerosis from Taiwan
|
Yang C.-C.; Yang C.-C.;Ro L.-S.;Tsai N.-W.;Lin C.-C.;Huang W.-N.;Tsai C.-P.;Lin T.-S.;Jen-Jen Su;Huang C.-C.;Lyu R.-K.;Chen H.-H.;Lee W.-J.;Chen P.-L.;Yang A.; Ro L.-S.; Tsai N.-W.; Lin C.-C.; Huang W.-N.; Tsai C.-P.; Lin T.-S.; JEN-JEN SU; Huang C.-C.; Lyu R.-K.; Chen H.-H.; Lee W.-J.; Chen P.-L.; Yang A. |
| 臺大學術典藏 |
2021-12-02T07:32:18Z |
Real-world evidence on the safety and effectiveness of fingolimod in patients with multiple sclerosis from Taiwan
|
Yang C.-C.; Ro L.-S.; Tsai N.-W.; Lin C.-C.; Huang W.-N.; Tsai C.-P.; Lin T.-S.; JEN-JEN SU; Huang C.-C.; Lyu R.-K.; Chen H.-H.; Lee W.-J.; Chen P.-L.; Yang A. |
| 國立成功大學 |
2021 |
Real-world evidence on the safety and effectiveness of fingolimod in patients with multiple sclerosis from Taiwan
|
Yang, C.-C.;Ro, L.-S.;Tsai, N.-W.;Lin, C.-C.;Huang, W.-N.;Tsai, C.-P.;Lin, T.-S.;Su, J.-J.;Huang, C.-C.;Lyu, R.-K.;Chen, H.-H.;Lee, W.-J.;Chen, P.-L.;Yang, A. |
| 國家衛生研究院 |
2020-08-02 |
Real-world evidence on the use of benzodiazepine receptor agonists and the risk of venous thromboembolism
|
Chen, TY;Winkelman, JW;Mao, WC;Tzeng, NS;Kuo, TBJ;Yang, CCH;Tsai, HJ;Wu, CS |
| 臺大學術典藏 |
2020-11-04T09:17:05Z |
Real-world evidence on the use of benzodiazepine receptor agonists and the risk of venous thromboembolism
|
Chen T.-Y.; Winkelman J.W.; Mao W.-C.; Tzeng N.-S.; Kuo T.B.J.; Yang C.C.H.; Tsai H.-J.; CHI-SHIN WU |
| 臺大學術典藏 |
2018-09-10T18:06:04Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang, S.-K. and Hsieh, M.-S. and Lee, M.-R. and Keng, L.-T. and Ko, J.-C. and Shih, J.-Y.; MENG-RUI LEE; KENG LI-TA; JEN-CHUNG KO; SHENG-KAI LIANG; JIN-YUAN SHIH |
| 臺大學術典藏 |
2020-03-05T08:04:03Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.;Min-Shu Hsieh;Lee M.-R.;Keng L.-T.;Ko J.-C.;Shih J.-Y.; Liang S.-K.; MIN-SHU HSIEH; Lee M.-R.; Keng L.-T.; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2020-08-13T06:33:37Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.;Hsieh M.-S.;Lee M.-R.;Keng L.-T.;Ko J.-C.;Jin-Yuan Shih; Liang S.-K.; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; Ko J.-C.; JIN-YUAN SHIH |
| 臺大學術典藏 |
2017 |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; MENG-RUI LEE; Keng L.-T.; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-01-08T03:40:20Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Shih J.-Y.; Ko J.-C.; Lee M.-R.; Keng L.-T.; Hsieh M.-S.; SHENG-KAI LIANG |
| 臺大學術典藏 |
2021-03-11T07:58:31Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; JEN-CHANG KO; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-11T08:29:35Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; JEN-CHANG KO; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-11T08:34:21Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.;Hsieh M.-S.;Lee M.-R.;Keng L.-T.;Jen-Chang Ko;Shih J.-Y.; SHENG-KAI LIANG; Min-Shu Hsieh; MENG-RUI LEE; LI-TA KENG; JEN-CHANG KO; Jin-Yuan Shih |
| 臺大學術典藏 |
2021-09-17T05:56:07Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; Lee M.-R.; LI-TA KENG; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-10-04T07:15:44Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; JEN-CHANG KO; Shih J.-Y. |
| 臺大學術典藏 |
2021-01-08T02:56:48Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.;Hsieh M.-S.;Lee M.-R.;Li-Ta Keng;Ko J.-C.;Shih J.-Y.; Liang S.-K.; Hsieh M.-S.; Lee M.-R.; LI-TA KENG; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-17T02:51:01Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; MENG-RUI LEE; Keng L.-T.; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-17T03:21:19Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
SHENG-KAI LIANG; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; Ko J.-C.; Shih J.-Y. |
| 中山醫學大學 |
2021 |
Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study
|
Su, PY; Su, WW; Hsu, YC; Huang, SP; Yen, HH |
| 國立成功大學 |
2024 |
Real-world experience of using dupilumab and JAK inhibitors to manage pruritus in epidermolysis bullosa pruriginosa
|
Hou;P, -C.;Aala;W;Tu;W, -T.;McGrath;J, A.;Hsu;C, -K. |
| 國立成功大學 |
2023 |
Real-world experience on intravitreal dexamethasone implant in patients with macular edema scheduled to undergo cataract surgery
|
Lai, C.-C.;Kuo, S.-C. |
| 臺大學術典藏 |
2021-05-06T01:25:13Z |
Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study
|
Liou B.-H.; Sun H.-Y.; Yang C.-J.; Syue L.-S.; Lee Y.-L.; Tang H.-J.; Tsai H.-C.; Lin C.-Y.; Chen T.-C.; Lee C.-Y.; Huang S.-H.; Liu C.-W.; Lu P.-L.; Lin S.-P.; Wang N.-C.; Cheng A.; Ko W.-C.; Cheng S.-H.; CHIEN-CHING HUNG; the Taiwan HIV Study Group |
| 臺大學術典藏 |
2021-08-16T08:36:11Z |
Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study
|
Liou B.-H.; Sun H.-Y.; Yang C.-J.; Syue L.-S.; Lee Y.-L.; Tang H.-J.; Tsai H.-C.; Lin C.-Y.; Chen T.-C.; Lee C.-Y.; Huang S.-H.; Liu C.-W.; Lu P.-L.; Lin S.-P.; Wang N.-C.; ARISTINE CHENG; Ko W.-C.; Cheng S.-H.; Hung C.-C.; the Taiwan HIV Study Group |
| 臺大學術典藏 |
2021-08-20T07:10:55Z |
Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study
|
Liou B.-H.; HSIN-YUN SUN; Yang C.-J.; Syue L.-S.; Lee Y.-L.; Tang H.-J.; Tsai H.-C.; Lin C.-Y.; Chen T.-C.; Lee C.-Y.; Huang S.-H.; Liu C.-W.; Lu P.-L.; Lin S.-P.; Wang N.-C.; Cheng A.; Ko W.-C.; Cheng S.-H.; Hung C.-C.; the Taiwan HIV Study Group |
| 國立成功大學 |
2021 |
Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study
|
Liou, B.-H.;Sun, H.-Y.;Yang, C.-J.;Syue, L.-S.;Lee, Y.-L.;Tang, H.-J.;Tsai, H.-C.;Lin, C.-Y.;Chen, T.-C.;Lee, C.-Y.;Huang, S.-H.;Liu, C.-W.;Lu, P.-L.;Lin, S.-P.;Wang, N.-C.;Cheng, A.;Ko, W.-C.;Cheng, S.-H.;Hung, C.-C.;Group, the Taiwan HIV Study |
| 嘉南藥理大學 |
2021 |
Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study
|
Liou, Bo-Huang; Sun, Hsin-Yun; Yang, Chia-Jui; Syue, Ling-Shan; Lee, Yu-Lin; Tang, Hung-Jen; Tsai, Hung-Chin; Lin, Chi-Ying; Chen, Tun-Chieh; Lee, Chun-Yuan; Huang, Sung-Hsi; Liu, Chia-Wei; Lu, Po-Liang; Lin, Shih-Ping; Wang, Ning-Chi; Cheng, Aristine; Ko, Wen-Chien; Cheng, Shu-Hsing; Hung, Chien-Ching |
| 臺大學術典藏 |
2020-03-05T06:05:32Z |
Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan
|
LI-KAI TSAI; Lin H.-J.; Chua S.-K.; Liao P.-C.; Yang Y.-P.; Chou P.-C.; Lee C.-W.; Lin M.-J.; Chen H.-M.; Yeh J.-T.; Li Y.-H. |
| 臺大學術典藏 |
2020-11-03T12:37:44Z |
Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan
|
Li-Kai Tsai;Lin H.-J.;Chua S.-K.;Liao P.-C.;Yang Y.-P.;Chou P.-C.;Lee C.-W.;Lin M.-J.;Chen H.-M.;Yeh J.-T.;Li Y.-H.; LI-KAI TSAI; Lin H.-J.; Chua S.-K.; Liao P.-C.; Yang Y.-P.; Chou P.-C.; Lee C.-W.; Lin M.-J.; Chen H.-M.; Yeh J.-T.; Li Y.-H. |
| 臺大學術典藏 |
2021-11-26T05:56:35Z |
Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan
|
LI-KAI TSAI; Lin H.-J.; Chua S.-K.; Liao P.-C.; Yang Y.-P.; Chou P.-C.; Lee C.-W.; Lin M.-J.; Chen H.-M.; Yeh J.-T.; Li Y.-H. |
| 國立成功大學 |
2018-02 |
Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan
|
Tsai;Li-Kai;Lin;Huey-Juan;Chua;Su-Kiat;Liao;Pen-Chih;Yang;Yuan-Po;Chou;Ping-Chen;Lee;Chun-Wei;Lin;Mao-Jen;Chen;Hsi-Ming;Yeh;Jung-Tze;Li;Yi-Heng |
| 國家衛生研究院 |
2024-08-12 |
Real-world insights from comprehensive genomic profiling across multiple cancer types
|
Hung, LJ;Huang, CY;Chen, JS;Huang, WK;Hsu, CC;Fang, YF;Wang, CL;Liu, PC;Yeh, KY;Chang, PH;Chang, JWC;Lin, YC;Huang, SF;Chou, WC |
| 臺大學術典藏 |
2021-08-15T00:08:17Z |
Real-world insights into patients with advanced NSCLC and MET alterations
|
Bittoni, Marisa; CHIH-HSIN YANG; JIN-YUAN SHIH; Peled, Nir; Smit, Egbert F.; Camidge, D. Ross; Arasada, Rajeswara Rao; Oksen, Dina; Boutmy, Emmanuelle; Stroh, Christopher; Johne, Andreas; Carbone, David P.; Paik, Paul K. |
| 臺大學術典藏 |
2021-11-03T02:33:00Z |
Real-world insights into patients with advanced NSCLC and MET alterations
|
Bittoni M.; Yang J.C.-H.; JIN-YUAN SHIH; Peled N.; Smit E.F.; Camidge D.R.; Arasada R.R.; Oksen D.; Boutmy E.; Stroh C.; Johne A.; Carbone D.P.; Paik P.K. |
| 臺大學術典藏 |
2022-08-10T02:37:40Z |
Real-world insights into patients with advanced NSCLC and MET alterations
|
Bittoni M.; CHIH-HSIN YANG; Shih J.-Y.; Peled N.; Smit E.F.; Camidge D.R.; Arasada R.R.; Oksen D.; Boutmy E.; Stroh C.; Johne A.; Carbone D.P.; Paik P.K. |
| 臺大學術典藏 |
2022-02-22T05:34:08Z |
Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
|
Kuo Y.-H.; Lu S.-N.; Chen Y.-Y.; Kee K.-M.; Yen Y.-H.; Hung C.-H.; Hu T.-H.; CHIEN-HUNG CHEN; Wang J.-H. |
| 臺大學術典藏 |
2022-02-23T02:12:18Z |
Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
|
Kuo Y.-H.; Lu S.-N.; Chen Y.-Y.; Kee K.-M.; Yen Y.-H.; Hung C.-H.; Hu T.-H.; CHIEN-HUNG CHEN; Wang J.-H. |
| 國立交通大學 |
2019-04-03T06:37:18Z |
Real-World Neuroimaging Technologies
|
McDowell, Kaleb; Lin, Chin-Teng; Oie, Kelvin S.; Jung, Tzyy-Ping; Gordon, Stephen; Whitaker, Keith W.; Li, Shih-Yu; Lu, Shao-Wei; Hairston, W. David |
| 臺大學術典藏 |
2020-05-26T09:26:29Z |
Real-World or Controlled Clinical Trial Data in Real-World Practice
|
Chih-Hsin Yang;Wu T.-H; Wu T.-H; CHIH-HSIN YANG |
| 國立成功大學 |
2024-05-16 |
Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer
|
Chang;Gee-Chen;Shih;Jin-Yuan;Yu;Chong-Jen;Chao;Heng-Sheng;Yang;Cheng-Ta;Lin;Chien-Chung;Hung;Jen-Yu;Hsiao;Sheng-Yen;Wang;Chin-Chou;Chian;Chih-Feng;Hsia;Te-Chun;Chen;Yuh-Min |
| 國立成功大學 |
2021-07 |
Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis
|
Tsai;Hong-Ming;Han;Meng-Zhi;Lin;Yih-Jyh;Chang;Ting-Tsung;Chen;Chiung-Yu;Cheng;Pin-Nan;Chuang;Chiao-Hsiung;Wu;I-Chin;Chen;Po-Jun;Kang;Jui-Wen;Chiu;Yen-Cheng;Chiu;Hung-Chih;Chien;Shih-Chieh;Kuo;Hsin-Yu |
| 國立成功大學 |
2021-7 |
Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis
|
郭欣瑜; Kuo, Shi-Yu; Tsai, Hong-Ming;Han, Meng-Zhi;Lin, Yih-Jyh;Chang, Ting-Tsung;Chen, Chiung-Yu;Cheng, Pin-Nan;Chuang, Chiao-Hsiung;Wu, I-Chin;Chen, Po-Jun;Kang, Jui-Wen;Chiu, Yen-Cheng;Chiu, Hung-Chih;Chien, Shih-Chieh;Kuo, Hsin-Yu |
| 國立成功大學 |
2019-10 |
Real-world outcomes of NSCLC patients receiving tissue or circulating tumor DNA-guided osimertinib treatment
|
Su;Po-Lan;Yang;Szu-Chun;Chen;Yi-Lin;Wu;Yi-Lin;Lin;Chia-Ying;Chang;Wei-Yuan;Tseng;Yau-Lin;Lai;Wu-Wei;Ho;Chung-Liang;Lin;Chien-Chung;Su;Wu-Chou |
| 臺大學術典藏 |
2021-09-14T23:18:37Z |
Real-World Outcomes of Patients with Acute Myeloid Leukemia in Taiwan: A Nationwide Population-Based Study, 2011-2015
|
Wang, Chen Yu; Huang, Huai Hsuan; Chen, Ho Min; FEI-YUAN HSIAO; BOR-SHENG KO |
| 臺大學術典藏 |
2022-09-19T03:16:34Z |
Real-World Outcomes of Patients with Acute Myeloid Leukemia in Taiwan: A Nationwide Population-Based Study, 2011-2015
|
Wang C.-Y.; Huang H.-H.; Chen H.-M.; FEI-YUAN HSIAO; Ko B.-S. |
